Follistatin 315 vs Kisspeptin-10
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 315Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10- Summary
- Follistatin 315 is a splice variant isoform of follistatin produced by alternative mRNA processing. Unlike Follistatin 344 which is tethered to cell surfaces via heparan sulfate proteoglycans, FST-315 circulates freely in the bloodstream and has broader systemic distribution. It is the predominant circulating form and exerts systemic myostatin inhibition as well as FSH suppression, making it relevant to both muscle growth and reproductive endocrinology.
- Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
- Half-Life
- ~3–5 hours (longer systemic circulation vs FST-344)
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- Admin Route
- SubQ, IM
- SubQ, IV
- Research
- —
- —
- Typical Dose
- No established human dosing protocol
- 50–500 mcg
- Frequency
- Research use only
- Once daily to every other day
- Key Benefits
- Systemic myostatin inhibition for whole-body muscle growth
- Freely circulating — broader tissue distribution than FST-344
- Strong FSH-suppressive activity useful in certain hormonal protocols
- Potential for greater anabolic effect across multiple muscle groups simultaneously
- May be more relevant to reproductive endocrinology applications
- Studied in gene therapy approaches for muscular dystrophy
- Potently stimulates LH and testosterone
- Enhances sexual arousal and libido
- Activates HPG axis — upstream of GnRH
- May improve fertility in hypogonadotropic hypogonadism
- Increases brain activation in sexual attraction circuits
- May restore LH pulsatility in suppressed HPG axis
- Side Effects
- Systemic FSH suppression — significant concern for fertility
- Greater potential for off-target effects vs FST-344 due to systemic distribution
- Limited human safety data
- Potential cardiac hypertrophy with prolonged high-dose exposure
- Injection site reactions
- Temporary nausea
- Flushing
- Elevated LH/testosterone (intended effect)
- +1 more
- Stacks With
- —
- —